CN100354302C - SIP gene and its coded protein and uses - Google Patents
SIP gene and its coded protein and uses Download PDFInfo
- Publication number
- CN100354302C CN100354302C CNB2005100111965A CN200510011196A CN100354302C CN 100354302 C CN100354302 C CN 100354302C CN B2005100111965 A CNB2005100111965 A CN B2005100111965A CN 200510011196 A CN200510011196 A CN 200510011196A CN 100354302 C CN100354302 C CN 100354302C
- Authority
- CN
- China
- Prior art keywords
- ala
- leu
- ser
- pro
- glu
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 39
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 20
- 101001046980 Homo sapiens KN motif and ankyrin repeat domain-containing protein 2 Proteins 0.000 title abstract description 29
- 239000003814 drug Substances 0.000 claims abstract description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 9
- 208000026310 Breast neoplasm Diseases 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 7
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 102100022888 KN motif and ankyrin repeat domain-containing protein 2 Human genes 0.000 abstract description 23
- 108060001084 Luciferase Proteins 0.000 abstract description 14
- 239000005089 Luciferase Substances 0.000 abstract description 13
- 230000004614 tumor growth Effects 0.000 abstract description 3
- 230000035755 proliferation Effects 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 50
- 239000000243 solution Substances 0.000 description 34
- 206010028980 Neoplasm Diseases 0.000 description 16
- 238000000034 method Methods 0.000 description 15
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 14
- 235000015097 nutrients Nutrition 0.000 description 14
- 235000018102 proteins Nutrition 0.000 description 14
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 238000009396 hybridization Methods 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- 150000001413 amino acids Chemical group 0.000 description 8
- 102220369446 c.1274G>A Human genes 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 102220023256 rs387907547 Human genes 0.000 description 8
- 102220023258 rs387907548 Human genes 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 238000001890 transfection Methods 0.000 description 7
- 108020004414 DNA Proteins 0.000 description 6
- 230000012010 growth Effects 0.000 description 6
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 5
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 5
- 230000004927 fusion Effects 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 238000000197 pyrolysis Methods 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 210000004907 gland Anatomy 0.000 description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 3
- 102000008102 Ankyrins Human genes 0.000 description 3
- 108010049777 Ankyrins Proteins 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 208000005243 Chondrosarcoma Diseases 0.000 description 3
- 241000254064 Photinus pyralis Species 0.000 description 3
- 108700008625 Reporter Genes Proteins 0.000 description 3
- 235000002254 Viola papilionacea Nutrition 0.000 description 3
- 244000225942 Viola tricolor Species 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 210000004696 endometrium Anatomy 0.000 description 3
- 210000003527 eukaryotic cell Anatomy 0.000 description 3
- 239000013613 expression plasmid Substances 0.000 description 3
- 239000003292 glue Substances 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 210000002826 placenta Anatomy 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000000452 restraining effect Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 210000001550 testis Anatomy 0.000 description 3
- 238000003146 transient transfection Methods 0.000 description 3
- 239000011534 wash buffer Substances 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- HBZBAMXERPYTFS-SECBINFHSA-N (4S)-2-(6,7-dihydro-5H-pyrrolo[3,2-f][1,3]benzothiazol-2-yl)-4,5-dihydro-1,3-thiazole-4-carboxylic acid Chemical compound OC(=O)[C@H]1CSC(=N1)c1nc2cc3CCNc3cc2s1 HBZBAMXERPYTFS-SECBINFHSA-N 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 108091092584 GDNA Proteins 0.000 description 2
- 108010024636 Glutathione Proteins 0.000 description 2
- 241000254158 Lampyridae Species 0.000 description 2
- 239000012097 Lipofectamine 2000 Substances 0.000 description 2
- 206010029260 Neuroblastoma Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- CWHJIJJSDGEHNS-MYLFLSLOSA-N Senegenin Chemical compound C1[C@H](O)[C@H](O)[C@@](C)(C(O)=O)[C@@H]2CC[C@@]3(C)C(CC[C@]4(CCC(C[C@H]44)(C)C)C(O)=O)=C4[C@@H](CCl)C[C@@H]3[C@]21C CWHJIJJSDGEHNS-MYLFLSLOSA-N 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- 239000006180 TBST buffer Substances 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 102220369447 c.1352G>A Human genes 0.000 description 2
- 102220369445 c.668T>C Human genes 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 238000005336 cracking Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 230000002934 lysing effect Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 210000002752 melanocyte Anatomy 0.000 description 2
- 206010027191 meningioma Diseases 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 description 2
- 230000004960 subcellular localization Effects 0.000 description 2
- 239000009871 tenuigenin Substances 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 201000005262 Chondroma Diseases 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 208000007433 Lymphatic Metastasis Diseases 0.000 description 1
- 208000028018 Lymphocytic leukaemia Diseases 0.000 description 1
- 208000000172 Medulloblastoma Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 108090001146 Nuclear Receptor Coactivator 1 Proteins 0.000 description 1
- 102100037223 Nuclear receptor coactivator 1 Human genes 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 241000233855 Orchidaceae Species 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 241000242739 Renilla Species 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 1
- YVNQAIFQFWTPLQ-UHFFFAOYSA-O [4-[[4-(4-ethoxyanilino)phenyl]-[4-[ethyl-[(3-sulfophenyl)methyl]amino]-2-methylphenyl]methylidene]-3-methylcyclohexa-2,5-dien-1-ylidene]-ethyl-[(3-sulfophenyl)methyl]azanium Chemical compound C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C(=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S(O)(=O)=O)C)C=2C(=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S(O)(=O)=O)C)C=C1 YVNQAIFQFWTPLQ-UHFFFAOYSA-O 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 238000007622 bioinformatic analysis Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 210000003161 choroid Anatomy 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 210000003477 cochlea Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 210000000695 crystalline len Anatomy 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
- 238000013016 damping Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 208000018529 duodenal adenocarcinoma Diseases 0.000 description 1
- 201000005839 duodenum adenocarcinoma Diseases 0.000 description 1
- 201000003908 endometrial adenocarcinoma Diseases 0.000 description 1
- 208000029382 endometrium adenocarcinoma Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 208000010932 epithelial neoplasm Diseases 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 206010016629 fibroma Diseases 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 238000012637 gene transfection Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000001102 germinal center b cell Anatomy 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 230000012447 hatching Effects 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 206010022498 insulinoma Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 208000003747 lymphoid leukemia Diseases 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 208000007538 neurilemmoma Diseases 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 210000001706 olfactory mucosa Anatomy 0.000 description 1
- 210000001328 optic nerve Anatomy 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 208000021255 pancreatic insulinoma Diseases 0.000 description 1
- 201000010198 papillary carcinoma Diseases 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 210000002976 pectoralis muscle Anatomy 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 208000023958 prostate neoplasm Diseases 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 206010039667 schwannoma Diseases 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 208000000649 small cell carcinoma Diseases 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000000273 spinal nerve root Anatomy 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000005477 standard model Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 210000005065 subchondral bone plate Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 210000001258 synovial membrane Anatomy 0.000 description 1
- 230000002277 temperature effect Effects 0.000 description 1
- 208000001608 teratocarcinoma Diseases 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000005758 transcription activity Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 208000024719 uterine cervix neoplasm Diseases 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 210000004885 white matter Anatomy 0.000 description 1
- 238000001086 yeast two-hybrid system Methods 0.000 description 1
Images
Landscapes
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
本发明涉及SIP基因,该基因编码的SIP蛋白,以及所述基因和蛋白在医学中的应用。所述蛋白能够抑制肿瘤的生长和增殖,对cyclinD1启动子启动荧光素酶表达起抑制作用。
The present invention relates to SIP gene, the SIP protein encoded by the gene, and the application of the gene and protein in medicine. The protein can inhibit tumor growth and proliferation, and can inhibit the expression of luciferase initiated by the cyclinD1 promoter.
Description
Technical field
The present invention relates to the SIP gene, the sip protein of this genes encoding, and described gene and the application of albumen in medical science.Described albumen can suppress growth of tumor and propagation, the cyclinD1 promotor is started luciferase expression play restraining effect.
Background technology
Some albumen can suppress the growth and the propagation of tumour cell, finds that the albumen of new inhibition tumor growth and propagation and their gene of coding can be tumor treatment new ways and means is provided.
Summary of the invention
The present invention has found a kind of growth of the cancer cells that suppresses mammary cancer etc. and the albumen of propagation, cloned this proteic gene of coding, made up the host cell that contains this expression carrier and contain this expression vector, and find that this albumen can suppress the growth and the propagation of tumour cells such as mammary cancer, based on above discovery, finished the present invention.
Therefore, in one aspect, the invention provides the growth that can suppress tumour cell and the albumen of propagation, especially recombinant protein, this albumen has the aminoacid sequence shown in the sequence 2 in the sequence table, perhaps by the one or more amino acid whose disappearance in the described aminoacid sequence, replace or increase and the aminoacid sequence that obtains.
In yet another aspect, the invention provides the above-mentioned proteic gene of coding, it be have the base sequence shown in the sequence 1 DNA or with the DNA of described DNA hybridize under stringent condition.
In yet another aspect, the invention provides and contain said gene or encode above-mentioned proteic expression carrier.
In yet another aspect, the invention provides by above-mentioned expression vector transformed host cells.
In yet another aspect, the invention provides the method for producing recombinant protein of the present invention, this method comprises the following steps:
Cultivate above-mentioned transformed host cells, make transformant produce recombinant protein of the present invention; With
From culture, isolate recombinant protein.
In yet another aspect, the invention provides at above-mentioned proteic antibody, the specific antibody that it is to use described recombinant protein to produce as immunogen.It can be mono-clonal or polyclonal antibody.
In yet another aspect, the invention provides and detect described proteic test kit, it contains above-mentioned specific antibody, can carry out antigen-antibody reaction, is used to detect have the albumen shown in the sequence 2.
In addition, the invention provides the probe diagnostics test kit that is used to detect the nucleotide sequence shown in the sequence 1, it contain with nucleotide sequence 1 in partial nucleotide sequence complementary nucleotide sequence.It can be a dna fragmentation with 15-300 base.By the method for probe hybridization, be used to detect the expression of the mRNA that contains described nucleotide sequence, this mRNA is translated into the albumen that contains the aminoacid sequence shown in the sequence 2.
In addition, it is right to the invention provides a primer, be used for carrying out pcr amplification, primer is as follows: Primer1:5 '-tgc tct aga gcc acc atg gac tac aaggac gac gat gac aag gaa ttc atg gcc cag gtc ctg cac-3 '
Primer2:5’-cgc?gga?tcc?cta?ctc?ttc?tgc?cga?gga-3’。
The present invention also provides the application in the medicine of preparation treatment tumour of said gene, albumen or antibody.
The accompanying drawing summary
Fig. 1 is that Northem Blot result shows: gene transcripts conforms to its total length size.And in 8 kinds of tissues of the mankind, expression is arranged all.Conform to the information biology prediction.
Fig. 2 is the polyacrylamide gel electrophoresis figure (SDS-PAGE) of GST-SIP fusion rotein expression and purification in e. coli bl21.90kDa is proteinic molecular weight.The arrow indication is isolated protein band.
Fig. 3 is the expression figure (Western blot) of sip protein in eukaryotic cell MCF-7.One anti-is mouse anti human Flag monoclonal antibody, and the two anti-anti-mouse horseradish peroxidase of rabbit (HRP) link coupled of preserving for this laboratory two resist.1 negative contrast, 2 is cell pyrolysis liquid.PcDNA3.1 (-)-SIP transfection of flag label of MCF-7 cell.Protein level is with anti-flag antibody test.The cell lysates of negative control and MCF-7 is represented in the 1-2 road respectively.
Fig. 4 is the Subcellular Localization of sip protein.Green is GFP, the karyon that blueness is dyed for DAPI.The Subcellular Localization of SIP is in tenuigenin.
Fig. 5 detects the influence of the SIP of different concns to breast cancer cell propagation for mtt assay.X-coordinate is the transfection time, and ordinate zou is the 570nm absorbance.In every prescription post, be v-25ng from left to right successively, SIP-25ng, v-50ng, SIP-50ng, v-100ng, SIP-100ng.
Fig. 6 is SIP starts luciferase expression to the cyclinD1 promotor effect.X-coordinate is the different deletant of cyclinD1 promotor.Ordinate zou is a Firefly/Renilla ratio.Fig. 7 is the structural representation of SIP, and two grey square frames are wherein served as reasons
Coils2 <http://smart.embl-heidelberg.de/help/smartglossary. shtml 〉The coiled coil of program determination zone and 6 black box be by
SEG <http://smart.embl-heidelberg.de/help/smartglossary.shtml 〉The low segment of measuring of composition complicacy.
SIP (SRC-1 interacting protein) is the SRC-1 by one of p160 family member The new gene that method by yeast two-hybrid screens. We are from people's mammary gland cDNA library In obtain the ORF of this gene by the method for PCR. Be cloned into pcDNA3.1 (-) eukaryotic expression In the carrier. For ease of detecting Flag label on its N termination. SIP is again KIAA1518, FLJ20004, DKFZp434N161. Be positioned chromosome 19p13.2. Total length 5358bp. Expressing protein~90kD. ORF:2580bp. 859 amino acid of encoding.
It is carried out bioinformatic analysis, find its wide spectrum expression. Comprise Ankyrin repeat Domain.
(1) SIP expressing information:
CDNA source: normal prostatic; Testis; Colon; Colon tumor, RER+; Pooled-Skin; Neuroblastoma COT 10 NORMALIZED; Primary pulmonary cystic fibrosis epithelial cell; Fat Fat; Malignant mela noma, lymphatic metastasis; White matter; Cochlea; Bone marrow matrix; Glioblastoma (pooled); Five kinds merge sarcoma, comprise MLS, single-shot fibroma, malignant fibrous Histocytoma, the stromal tumors tumour of stomach and intestine, and celiothelioma; Small cell carcinoma; Placenta; Lymph; Three kinds merge meningioma; Full brain; Moderate differentiation adenocarcinoma of endometrium, 3 kinds merge tumour; Normally Colon; Chondrosarcoma lung transfer cell line; Medulloblastoma; Tumour; Ovary; The B cell, slow The property lymphocytic leukemia; Epithelioma; Melanoma; Breast; The slurries papillary carcinoma, senior, 2 kinds Merge tumour; Normal testis; Whole embryo mainly is body; Ovarian carcinoma; Prostate; Sympathetic trunk; Liver and spleen; Meningioma; Normal prostatic; Kidney neoplasms; Iris; Crystalline lens; Olfactory epithelium; Placenta; Neck; Normal placenta; Normal endometrium, middle secretory phase, the 23rd cycle Day; Melanocyte; Merge human melanocytes, fetal rhythm, and gravid uterus; Kidney; Gland cancer; Having seal guards against The poorly differentiated gland cancer of cell characteristic; Merge; Normal coloring look epithelium; Melanoma, high MDR is (thin Born of the same parents system); Epithelial cancer cell line; Neuroblastoma; Cervical cancer tumer line; Hippocampus; The brain that merges, Lung, testis; Optic nerve; Cervix tumor; Fetal pancreas (4 Pooled Donors, 18-20 Week, stratagene); The fetus eyes; Old and feeble fibroblast; Ascites; Lung; On the elementary lung Chrotoplast; Tuberculosis kitchen range fibrillatable; The metastatic chondrosarcoma; Chondrosarcoma; Bad differone Endometrium Gland cancer, 2 kinds merge tumour; The uterus; Squamous cell carcinoma; The multiple sclerosis pathology; Insulinoma; Spleen; Squamous cell carcinoma, clone; Retinoblastoma; Mix (pool of 40 RNAs); Interior life Chondroma clone; Subchondral bone; Heart; Lung; Benign tumour; Duodenal adenocarcinoma, clone; Endometrium, gland cell system; Blood; People's pulmonary epithelial cells; The eyes leading portion; The dorsal root nerve Joint; Teratocarcinoma, clone; The RPE/ choroid; Clone; The purifying Langerhans' islands; Smooth muscle Knurl; Germinal center B cell; MDA; Pancreas; Synovial membrane; Chest muscle (mastectomy with Afterwards); Thyroid gland; The neurinoma tumour; Tumor of prostate.
(2) on the amino acid sequence basis, by ExPASy and interPro its major function is tied Functional domain a: Ankyrin is found in the prediction of structure territory. Detail See Figure and table: Fig. 1 is the structural representation of SIP, and two grey square frames are wherein served as reasonsCoils2 <http://smart.embl-heidelberg.de/help/smart glossary.shtml>The coiled coil of program determination zone and 6 black box be bySEG <http://smart.embl-heidelberg.de/help/smartglossary.shtml>The group of measuring Become the low segment of complexity.
Method | AccNumber | ahortName | Iocation-1 | Evalue | Iocation-2 | Evalue | Iocation-3 | Evalue | Iocation-4 | Evalue |
FPrintScan | PR01415 | ANKYRIN | T[675-687] | 2.8 | T[687-699] | 2.8 | ||||
HMMPfam | PF00023 | Ank | T[674-707] | 0.00026 | T[746-778] | 7.00E-11 | T[779-812] | 3.90E-06 | T[813-833] | 0.008 |
HMMSmart | SM00248 | ANK | T[674-704] | 0.0045 | T[708-741] | 8.00E+02 | T[746-775] | 6.30E-05 | T[779-809] | 0.024 |
ProfileScan | PS50088 | ANK_REPEAT | T[674-699] | 9.725 | T[748-778] | 12743 | ||||
ProfileScan | PS50297 | ANK_REP_REGION | T[668-836] | 31.086 |
The polypeptide of equivalence on the albumen of the application of the invention or the immunology can obtain it and resist Body, antibody is used for detection and the purifying of described albumen. Can utilize albumen of the present invention or its one Divide amino acid sequence originally to produce antibody as immunity. Can be moving by antibody being inoculated to the host Thing and the conventional method that reclaims serum produce polyclonal antibody. Can also pass through conventional hybridization knurl side Method produces monoclonal antibody.
Utilize mtt assay to detect the SIP of variable concentrations to the impact of MCF-7 tumor cell proliferation, Found that GIBC has the effect of inhibition tumor cell propagation.
Therefore, albumen of the present invention can be used for treating tumour, especially breast cancer.
Embodiment
Embodiment 1: with the gene of PCR method from human breast carcinoma cDNA library clone coding sip protein
With mammary cancer cDNA library is template, and Flag label on SIP gene N termination carries out pcr amplification with following primer:
Primer1:5’-tgc?tct?aga?gcc?acc?atg?gac?tac?aag?gacgac?gat?gac?aag?gaa?ttc?atg?gcc?cag?gtcctg?cac-3’
Primer2:5’-cgc?gga?tcc?cta?ctc?ttc?tgc?cga?gga-3’
The condition of amplified reaction: in the reaction volume of 50 μ L, contain 50mmol/L KCl, 10mmol/L Tris-Cl, (PH:8.5), 1.5mmol/L MgCl
2, 200 μ mol/L dNTP, 10pmol primer, the pfu archaeal dna polymerase of 0.25U (Takara company product).Press 30 cycles of following conditioned response: 94 ℃ of 30sec; 59 ℃ of 30sec; 72 ℃ of 2min 30sec.Amplified production is with the test kit purifying of QIAGEN company, behind XbaI and BamHI double digestion, is cloned in pcDNA3.1 (-) carrier for expression of eukaryon that same enzyme cuts.The dna sequence analysis result shows that the dna sequence dna of PCR product conforms to expection.
Embodiment 2:Northern Blot
The mark of probe and crossover operation are with reference to the Spotlight of Clontech company
TMRandomPrimer Labeling Kit test kit specification sheets.Process is as follows:
(1) probe mark: 25ng-1 μ gDNA is dissolved in the 20 μ L volumes, 90-100 ℃ 2-3 minute, rapidly ice bath is 5 minutes, add 5 μ L[α-
32P] the RandomPrimers and Reaction Buffer Mix of dCTP mark, moisturizing to 50 μ L is hatched 5-10min for 37 ℃.
(2) hybridization: 68 ℃ of preheating hybridization solutions, the nylon membrane that is adsorbed with nucleic acid is put into the hybridization bottle that contains hybridization solution, add the hybridization solution 0.1mL/cm of the salmon sperm DNA that contains 100 μ g/mL
2, 68 ℃ of prehybridization 30min.The 20ng/mL probe is sneaked into hybridization solution, 95 ℃ 2-5 minute, ice bath 5 minutes.Add the hybridization bottle, hybridized 1 hour for 68 ℃.
(3) wash film: washed film 30-40 minute with Wash Buffer 1 room temperature, washed film 40 minutes with 250 ℃ of Wash Buffer.
(4) colour developing: take out film with tweezers, wash and do Wash Buffer 2, cover with preservative film ,-70 ℃ of exposures were developed photographic fixing after 1-3 days.
Expression and the purifying of embodiment 3:SIP in prokaryotic cell prokaryocyte
PGEX-4T-3-SIP can be in e. coli strain bl21 the fusion rotein of 30 ℃ of abduction delivering GST-SIP, at first prepare the competent cell of BL21: the picking mono-clonal is in an amount of substratum, and 37 ℃ of 250rpm are cultured to A
6000.4-0.5, centrifugal 15 minutes of 2500g, standby.1-50ng pGEX-4T-3-SIP is transformed in the competent cell of above-mentioned preparation, carries out purifying with Glutathione Sepharose 4B, the step of purifying is as follows:
(1) getting mono-clonal cultivated 4-5 hour in 2-3mL 2YTA substratum.Be transferred to grow overnight in the Erlenmeyer flask of 100mL.
(2) be transferred in the Erlenmeyer flask of 500mL and cultivated 3-5 hour.
(3) add 30 ℃ of 0.5mL 1M IPTG, cultivated 3-6 hour.
(4) 10 minutes centrifugal collecting cells of 3000rpm.
(5) use the 25mLPBS re-suspended cell.Ultrasonic 10 minutes.
(6) add 1.25mL 20%Triton X-100, mixing 1 hour.
(7) 1000rpm 10 minutes is centrifugal, adds 0.5mL 50%slurry of Glutathione
Sepharose 4B, room temperature 30 minutes.
(8) 1000rpm 5 minutes is centrifugal, and PBS gives a baby a bath on the third day after its birth time.
(9) with 0.5mL wash-out Buffer wash-out, supernatant is collected in of short duration centrifugal back.
The expression of embodiment 4:SIP in eukaryotic cell
Western Blot grows up on the basis of protein electrophorese and solid-phase immunoassay.Its ultimate principle is antigen antibody reaction.The cell protein extract is transferred to (nitrocellulose filter is adopted in this experiment) on the solid support after polyacrylamide gel electrophoresis separates.(the anti-people Flag of this laboratory mice monoclonal antibody Sigma), is hatched with horseradish peroxidase (HRP) link coupled two anti-(it is anti-that the anti-mouse of rabbit two is preserved in this laboratory) again, and colour developing can obtain the western blot figure of differential protein molecule with special one anti-reaction.This method has detect specific antigenic advantage from mixes antigen, so this experiment is used to detect the expression behind the SIP gene transfection MCF-7 cell that has the Flag label.
1) transient transfection experiment:
In transfection the day before yesterday with the MCF-7 cell inoculation in the 10cm culture plate, inoculum density is 2 * 10
6Individual cells/well, every hole adds nutrient solution 10ml.After 24 hours, cell grows to when covering the about 50-60% of culture hole floorage, can prepare transfection.The following solution of preparation in the EP pipe: solution A: 24 μ g pcDNA3.1 (-)-SIP expression plasmid are dissolved in the unparalleled anti-DMEM nutrient solution of 1.5mL serum-free.Solution B: 48 μ L liposome solutions (lipofectamine 2000 reagent) are joined in the unparalleled anti-DMEM nutrient solution of 1.5mL serum-free.Room temperature left standstill 5 minutes.Then solution A, B are mixed, room temperature left standstill 20 minutes.With serum-free with do not contain two anti-DMEM nutrient solution washed cells.With adding the unparalleled anti-DMEM nutrient solution of 12mL serum-free in the mixed solution of above-mentioned solution A, B, add to cell surface behind the mixing.37 ℃, hatch 4-6 hour under the 5%CO2 condition after, replace aforementioned nutrient solution with the DMEM nutrient solution that normally contains 10% foetal calf serum again, continue culturing cell to 48 hour.
2) extraction of total protein of cell:
Cultured cells makes it to disperse through 0.25% trysinization, and 4 ℃ of low-speed centrifugals remove supernatant, and precipitation is placed 30min on ice, and the PBS with precooling washes per 10 2 times again
6Cell adds lysate 100 μ L, makes the abundant cracking 30min of cell, and again in 4 ℃, the centrifugal 15min of 20000 * g collects supernatant.
3) the Bradford method is measured the proteic concentration of cell pyrolysis liquid:
At first prepare coomassie brilliant blue staining liquid; Standard bovine serum albumin (BSA) is mixed with the protein standard liquid of 1mg/ml, 10 μ g, 20 μ g, 30 μ g, 40 μ g, 50 μ g, 60 μ g protein standard liquid and 5 μ L testing protein quality samples are added in the 3mL Xylene Brilliant Cyanine G dye liquor respectively, incubated at room 10min measures absorption value at 595nm wavelength place.BSA standard model bioassay standard curve, OD within the specific limits
595Be directly proportional with protein concentration.The concentration of sample protein matter is calculated through the typical curve fit equation.4) electrophoresis and immune response: flow process is as follows: A, glue (5% concentrates glue, 10% separation gel); B, 50 μ g protein samples add sample-loading buffer, boil last sample; C, electrophoresis concentrate glue 80V voltage, separation gel 120V voltage; D, commentaries on classics film, 100V, 1.5h; E, sealing, 1h; F, an anti-reaction, are spent the night by 4 ℃; G, TBST wash film, and three times, each 10min; H, two anti-reactions, 1.5h; I, TBST wash film, and three times, each 10min; J, colour developing, exposure.
Embodiment 5:SIP is in intracellular location
The pEGFP-C1 C-terminal albumen fusion vector that utilizes this laboratory to preserve has made up the pEGFP-C1-SIP carrier, and it can express the fusion rotein of GFP-SIP in eukaryotic cell, with this carrier Lipofectin
TMThe method transfection advance in the MCF-7 cell, cells transfected is carried out creep plate, after 24 hours, gives a baby a bath on the third day after its birth time with PBS, fixes with 4% Paraformaldehyde 96/PBS, room temperature 15 minutes is given a baby a bath on the third day after its birth time with PBS then.With saturatingization of 0.1%Triton X-100/PBS 15 minutes, give a baby a bath on the third day after its birth time with PBS then, add the DAPI of 200 μ L 2.5mg/mL, room temperature effect 30 minutes, give a baby a bath on the third day after its birth time with PBS then, under fluorescent microscope, observe with conventional wavelength of fluorescence and DAPI wavelength respectively, and take pictures.The results are shown in Figure 4, be positioned tenuigenin.
Embodiment 6:MTT method detects the influence of the SIP of different concns to breast cancer cell propagation
MTT (tetramethyl-azo azoles orchid) can be by cellular uptake, and is reduced into a kind of water-fast bluish voilet product first a ceremonial jade-ladle, used in libation by mitochondrial dehydrogenase in the viable cell, and is deposited in the cell, and dead cell does not have this function.The first a ceremonial jade-ladle, used in libation dissolves in dimethyl sulfoxide (DMSO) (DMSO), and solution has maximum absorption at the 570nm place.So the big more representative survivaling cell of this wave band place absorption value amount is many more.Mtt assay is widely used in cytotoxicity experiment, cell growth measurement etc.This experiment utilizes mtt assay to observe the influence of SIP to the MCF-7 growth.Concrete operation method is as follows:
In 96 orifice plates, every hole inoculating cell number is 1 * 10 with the MCF-7 cell inoculation of cultivating logarithmic phase
4Individual.Add SIP (25,50,100ng) according to concentration gradient next day, every mass action 6 porocytes, and 37 ℃, 5%CO2 cultivates.After cultivating 1d, 2d, 3d, 4d respectively, the MTT solution that in each cell cultures hole, adds 50 μ lL 1mg/mL, same culture condition effect down took out after 4 hours, liquid in the careful every hole of sucking-off, every hole adds dimethyl sulfoxide (DMSO) 150 μ L, slight vibration 10 minutes fully is dissolved in the dimethyl sulfoxide (DMSO) bluish voilet crystallization.Measure in 96 orifice plates every hole at the light absorption value at 570nm place with automatic microplate reader.Referring to Fig. 5, the MTT experiment shows that SIP plays restraining effect to the MCF-7 growth and proliferation of cell, and relevant with dosage.
Embodiment 7: transient transfection and luciferase (Luciferase) experiment:
Use luciferase as reporter gene, for the controlling element of analyzing gene with measure the method that the genetic transcription activity is provided convenience.This experiment is building up to cyclinD1 gene promoter and luciferase reading frame in the carrier for expression of eukaryon exactly jointly, with this fusion expression plasmid transfectional cell, by measuring the activity of luciferase, thereby the research transcription factor, regulate the effect of albumen to the cyclinD1 gene promoter.It is reporter gene that Photinus pyralis LUC (Firefly) is adopted in experiment, and extra large wild pansy (Renillar) luciferase is an internal reference.With two fluorescence report gene alaysis system test kits that Promega company produces, in same test tube, measure the activity of two kinds of enzymes.And the applied chemistry light-emitting appearance detects.
2) transient transfection experiment:
In transfection the day before yesterday with the MCF-7 cell inoculation in 24 well culture plates, inoculum density is 1-2 * 10
5Individual cells/well, every hole adds nutrient solution 0.5mL.After 24 hours, cell grows to when covering the about 50-60% of culture hole floorage, can prepare transfection.The following solution of preparation in the EP pipe: solution A: 0.8 μ gDNA (cyclinD1 reporter gene plasmid: 200ng; Confidential reference items Renillar plasmid: 10ng; SIP expression plasmid: 600ng or pcDNA3.1 (-) empty carrier plasmid: 600ng), be dissolved in the unparalleled anti-DMEM nutrient solution of 50 μ L serum-frees.Solution B: 2 μ L liposome solutions (lipofectamine 2000 reagent) are joined in the unparalleled anti-DMEM nutrient solution of 50 μ L serum-frees.Room temperature left standstill 5 minutes.Then solution A, B are mixed, room temperature left standstill 20 minutes.With serum-free with do not contain two anti-DMEM nutrient solution washed cells.With adding the unparalleled anti-DMEM nutrient solution of 400 μ L serum-frees in the mixed solution of above-mentioned solution A, B, add to cell surface behind the mixing.Each experimental group repeats 3 holes.37 ℃, 5%CO
2After hatching 4-6 hour under the condition, replace aforementioned nutrient solution with the DMEM nutrient solution that normally contains 10% foetal calf serum again, continue culturing cell to 48 hour.Lysing cell, the activity of measurement luciferase.
2) with pair activity of the two luciferases of fluorescence report kit genes measurement:
(1) lysing cell:
Clean cell with cold PBS, 100 μ L add each cell cultures hole with 1 * cell pyrolysis liquid (PLB), and incubated at room 15 minutes makes the abundant cracking of cell.Resulting cell pyrolysis liquid can be directly used in fluorescence measurement.
(2) preparation of luciferase substrate:
Photinus pyralis LUC substrate freezing dry powder is dissolved in the 10mL luciferase analysis buffer, and gained solution is LARII, packing ,-70 ℃ of preservations.
Use Stop﹠amp; The Glo damping fluid is diluted to 1 with 50 * extra large wild pansy luciferase substrate *, gained solution is Stop﹠amp; Glo, matching while using.
(3) measuring process:
20 μ L cell pyrolysis liquids are put into 96 hole fluorescence measurement plates, add 100 μ LLARII, measure Photinus pyralis LUC, measuring condition is: postpone 2 seconds, measured 10 seconds.
Add 100 μ LStop﹠amp again; Glo measures extra large wild pansy luciferase, and measuring condition is the same.
Referring to Fig. 6, SIP starts luciferase expression to the cyclinD1 promotor and plays restraining effect.
SIP preface ~ 1
SEQUENCE?LISTING
<110〉Peking University
<120〉SIP gene and encoded protein thereof and application
<130>
<160>2
<170>PatentIn?version?3.1
<210>1
<211>2580
<212>DNA
<213〉people
<220>
<221>CDS
<222>(1)..?(2577)
<223>
<400>1
atg?gcc?cag?gtc?ctg?cac?gtg?cct?gct?ccc?ttc?cca?ggg?acc?cct?ggc 48
Met?Ala?Gln?Val?Leu?His?Val?Pro?Ala?Pro?Phe?Pro?Gly?Thr?Pro?Gly
1 5 10 15
cca?gcc?tcc?cca?cct?gcc?ttc?cct?gcc?aag?gac?ccc?gat?cca?ccc?tac 96
Pro?Ala?Ser?Pro?Pro?Ala?Phe?Pro?Ala?Lys?Asp?Pro?Asp?Pro?Pro?Tyr
20 25 30
tcc?gtg?gag?acc?ccc?tat?ggc?tac?cgc?ctg?gac?ctg?gac?ttc?ctc?aag 144
Ser?Val?Glu?Thr?Pro?Tyr?Gly?Tyr?Arg?Leu?Asp?Leu?Asp?Phe?Leu?Lys
35 40 45
tac?gtg?gat?gac?atc?gag?aag?ggc?cac?acg?ctg?cga?cgc?gtg?gca?gtg 192
Tyr?Val?Asp?Asp?Ile?Glu?Lys?Gly?His?Thr?Leu?Arg?Arg?Val?Ala?Val
50 55 60
cag?cgc?cgc?ccc?cgc?ctg?agc?tcg?ctg?ccc?cgt?ggc?cct?ggc?tcc?tgg 240
Gln?Arg?Arg?Pro?Arg?Leu?Ser?Ser?Leu?Pro?Arg?Gly?Pro?Gly?Ser?Trp
65 70 75 80
tgg?acg?tcc?act?gag?tcg?ctg?tgc?tcc?aat?gcc?agt?ggg?gac?agc?cgc 288
Trp?Thr?Ser?Thr?Glu?Ser?Leu?Cys?Ser?Asn?Ala?Ser?Gly?Asp?Ser?Arg
85 90 95
cac?tca?gcc?tat?tcc?tac?tgc?ggc?cgt?ggc?ttc?tac?cct?cag?tat?ggt 336
His?Ser?Ala?Tyr?Ser?Tyr?Cys?Gly?Arg?Gly?Phe?Tyr?Pro?Gln?Tyr?Gly
100 105 110
gct?ctg?gag?acc?cgc?ggt?ggc?ttc?aat?ccg?cgg?gtg?gag?cgc?acg?ctg 384
Ala?Leu?Glu?Thr?Arg?Gly?Gly?Phe?Asn?Pro?Arg?Val?Glu?Arg?Thr?Leu
115 120 125
ctg?gat?gcc?cgt?cgc?cgt?ctc?gag?gac?cag?gcg?gcc?aca?ccc?acc?ggc 432
Leu?Asp?Ala?Arg?Arg?Arg?Leu?Glu?Asp?Gln?Ala?Ala?Thr?Pro?Thr?Gly
130 135 140
ctg?ggc?tcc?ctg?acc?ccc?agt?gcg?gcc?ggc?tcg?aca?gcc?tcc?ctg?gtg 480
Leu?Gly?Ser?Leu?Thr?Pro?Ser?Ala?Ala?Gly?Ser?Thr?Ala?Ser?Leu?Val
145 150 155 160
ggc?gtg?ggg?ttg?cca?ccc?ccg?aca?cca?cgg?agt?tca?gga?ctg?tcc?aca 528
Gly?Val?Gly?Leu?Pro?Pro?Pro?Thr?Pro?Arg?Ser?Ser?Gly?Leu?Ser?Thr
165 170 175
ccg?gtg?cct?ccc?agt?gcc?ggg?cac?ctg?gcc?cac?gtg?cgg?gag?cag?atg 576
Pro?Val?Pro?Pro?Ser?Ala?Gly?His?Leu?Ala?His?Val?Arg?Glu?Gln?Met
180 185 190
gcg?ggt?gcc?ctg?cgg?aag?ctg?cgg?cag?ctg?gag?gag?cag?gtg?aag?ctg 624
Ala?Gly?Ala?Leu?Arg?Lys?Leu?Arg?Gln?Leu?Glu?Glu?Gln?Val?Lys?Leu
195 200 205
atc?cct?gtg?ctc?cag?gtg?aag?ctc?tcg?gtg?ctc?cag?gag?gaa?aag?cgg 672
Ile?Pro?Val?Leu?Gln?Val?Lys?Leu?Ser?Val?Leu?Gln?Glu?Glu?Lys?Arg
210 215 220
cag?ctc?aca?gta?caa?ctt?aag?agc?cag?aag?ttc?ctg?ggc?cac?ccc?aca 720
Gln?Leu?Thr?Val?Gln?Leu?Lys?Ser?Gln?Lys?Phe?Leu?Gly?His?Pro?Thr
225 230 235 240
gcg?ggc?cgg?ggt?cgc?agc?gag?ctc?tgc?ctg?gac?ctc?ccc?gat?ccc?cca 768
Ala?Gly?Arg?Gly?Arg?Ser?Glu?Leu?Cys?Leu?Asp?Leu?Pro?Asp?Pro?Pro
245 250 255
gag?gac?cca?gtg?gca?ctg?gag?acc?cgg?agt?gtg?ggc?acc?tgg?gtc?cga 816
Glu?Asp?Pro?Val?Ala?Leu?Glu?Thr?Arg?Ser?Val?Gly?Thr?Trp?Val?Arg
260 265 270
gaa?cgg?gac?ttg?ggc?atg?cct?gat?ggg?gag?gct?gcc?ctc?gcc?gcc?aag 864
Glu?Arg?Asp?Leu?Gly?Met?Pro?Asp?Gly?Glu?Ala?Ala?Leu?Ala?Ala?Lys
275 280 285
gtc?gct?gtg?ctg?gag?acc?cag?ctc?aag?aag?gcg?ctt?cag?gag?ctg?cag 912
Val?Ala?Val?Leu?Glu?Thr?Gln?Leu?Lys?Lys?Ala?Leu?Gln?Glu?Leu?Gln
290 295 300
gca?gct?cag?gcc?cgg?cag?gct?gac?ccc?cag?ccc?cag?gcc?tgg?cca?ccg 960
Ala?Ala?Gln?Ala?Arg?Gln?Ala?Asp?Pro?Gln?Pro?Gln?Ala?Trp?Pro?Pro
305 310 315 320
ccg?gac?agc?ccg?gtc?cgc?gtg?gat?aca?gtc?cgg?gtg?gta?gaa?ggg?cca 1008
Pro?Asp?Ser?Pro?Val?Arg?Val?Asp?Thr?Val?Arg?Val?Val?Glu?Gly?Pro
325 330 335
cgg?gag?gtg?gag?gtg?gtg?gcc?agc?aca?gcc?gct?ggc?gcc?ccc?gca?cag 1056
Arg?Glu?Val?Glu?Val?Val?Ala?Ser?Thr?Ala?Ala?Gly?Ala?Pro?Ala?Gln
340 345 350
cgg?gcc?cag?agc?ctg?gag?cct?tac?ggc?aca?ggg?ctg?agg?gcc?ctg?gca 1104
Arg?Ala?Gln?Ser?Leu?Glu?Pro?Tyr?Gly?Thr?Gly?Leu?Arg?Ala?Leu?Ala
355 360 365
atg?cct?ggt?agg?cct?gag?agc?cca?cct?gtg?ttc?cgc?agc?cag?gag?gtg 1152
Met?Pro?Gly?Arg?Pro?Glu?Ser?Pro?Pro?Val?Phe?Arg?Ser?Gln?Glu?Val
370 375 380
gtg?gag?aca?atg?tgc?cca?gtg?ccc?gct?gca?gct?acc?agc?aac?gtc?cat 1200
Val?Glu?Thr?Met?Cys?Pro?Val?Pro?Ala?Ala?Ala?Thr?Ser?Asn?Val?His
385 390 395 400
atg?gtg?aag?aag?att?agc?atc?aca?gag?cga?agc?tgc?gat?gga?gca?gca 1248
Met?Val?Lys?Lys?Ile?Ser?Ile?Thr?Glu?Arg?Ser?Cys?Asp?Gly?Ala?Ala
405 410 415
ggc?ctc?cca?gaa?gtt?cct?gcc?gaa?tcg?tct?tcg?tca?ccc?ecg?ggg?tcc 1296
Gly?Leu?Pro?Glu?Val?Pro?Ala?Glu?Ser?Ser?Ser?Ser?Pro?Pro?Gly?Ser
420 425 430
gag?gta?gcc?tcc?ctt?aca?cag?cct?gag?aag?agc?aca?ggc?cga?gtg?ccc 1344
Glu?Val?Ala?Ser?Leu?Thr?Gln?Pro?Glu?Lys?Ser?Thr?Gly?Arg?Val?Pro
435 440 445
acc?cag?gag?ccc?acc?cac?agg?gag?ccc?acc?agg?caa?gca?gcc?tcc?caa 1392
Thr?Gln?Glu?Pro?Thr?His?Arg?Glu?Pro?Thr?Arg?Gln?Ala?Ala?Ser?Gln
450 455 460
gag?tcc?gag?gag?gcc?ggg?ggc?acc?gca?cct?ccg?ctg?tcc?tcc?cct?cca 1440
Glu?Ser?Glu?Glu?Ala?Gly?Gly?Thr?Ala?Pro?Pro?Leu?Ser?Ser?Pro?Pro
465 470 475 480
ggc?ggg?ccc?ccg?gca?ggc?gtg?cga?tct?atc?atg?aaa?cgg?aaa?gag?gag 1488
Gly?Gly?Pro?Pro?Ala?Gly?Val?Arg?Ser?Ile?Met?Lys?Arg?Lys?Glu?Glu
485 490 495
gtt?gca?gac?ccc?acg?gcc?cac?cgg?agg?agc?ctc?cag?ttc?gtg?ggg?gtc 1536
Val?Ala?Asp?Pro?Thr?Ala?His?Arg?Arg?Ser?Leu?Gln?Phe?Val?Gly?Val
500 505 510
aac?ggc?ggg?tat?gag?tcg?tca?tcc?gag?gac?tcc?agc?aca?gca?gag?aac 1584
Asn?Gly?Gly?Tyr?Glu?Ser?Ser?Ser?Glu?Asp?Ser?Ser?Thr?Ala?Glu?Asn
515 520 525
atc?tca?gac?aac?gac?agc?aca?gag?aac?gag?gcc?cca?gag?ccg?agg?gag 1632
Ile?Ser?Asp?Asn?Asp?Ser?Thr?Glu?Asn?Glu?Ala?Pro?Glu?Pro?Arg?Glu
530 535 540
agg?gtt?ccg?agt?gtg?gcc?gaa?gcc?ccc?cag?ctc?agg?cct?gca?ggg?acg 1680
Arg?Val?Pro?Ser?Val?Ala?Glu?Ala?Pro?Gln?Leu?Arg?Pro?Ala?Gly?Thr
545 550 555 560
gca?gcg?gcc?aag?acc?agc?cgg?cag?gag?tgt?cag?ctg?tct?cga?gaa?tct 1728
Ala?Ala?Ala?Lys?Thr?Ser?Arg?Gln?Glu?Cys?Gln?Leu?Ser?Arg?Glu?Ser
565 570 575
cag?cac?ata?ccc?act?gct?gag?ggg?gca?tca?gga?tca?aac?acg?gag?gag 1776
Gln?His?Ile?Pro?Thr?Ala?Glu?Gly?Ala?Ser?Gly?Ser?Asn?Thr?Glu?Glu
580 585 590
gag?atc?agg?atg?gag?cta?agc?cct?gac?ctc?atc?tca?gcc?tgc?ttg?gcc 1824
Glu?Ile?Arg?Met?Glu?Leu?Ser?Pro?Asp?Leu?Ile?Ser?Ala?Cys?Leu?Ala
595 600 605
ctg?gaa?aag?tac?ctg?gac?aat?ccc?aac?gcc?ctc?aca?gag?cgg?gag?ctg 1872
Leu?Glu?Lys?Tyr?Leu?Asp?Asn?Pro?Asn?Ala?Leu?Thr?Glu?Arg?Glu?Leu
610 615 620
aaa?gtg?gcc?tac?acc?aca?gtg?ctg?cag?gag?tgg?ctg?cgc?ctg?gcc?tgc 1920
Lys?Val?Ala?Tyr?Thr?Thr?Val?Leu?Gln?Glu?Trp?Leu?Arg?Leu?Ala?Cys
625 630 635 640
cgc?agc?gac?gca?cac?ccc?gag?ctg?gtg?cgg?cgg?cac?ctg?gtc?acg?ttc 1968
Arg?Ser?Asp?Ala?His?Pro?Glu?Leu?Val?Arg?Arg?His?Leu?Val?Thr?Phe
645 650 655
cgg?gcc?atg?tct?gcg?cgg?ctg?ctg?gac?tac?gtg?gtc?aac?atc?gcc?gac 2016
Arg?Ala?Met?Ser?Ala?Arg?Leu?Leu?Asp?Tyr?Val?Val?Asn?Ile?Ala?Asp
660 665 670
agc?aac?ggc?aac?aca?gcc?ctg?cac?tac?tcc?gtg?tct?cat?gcc?aac?ttc 2064
Ser?Asn?Gly?Asn?Thr?Ala?Leu?His?Tyr?Ser?Val?Ser?His?Ala?Asn?Phe
675 680 685
ccc?gtg?gtg?cag?cag?ctg?ctc?gac?agc?ggt?gtc?tgc?aag?gtg?gac?aaa 2112
Pro?Val?Val?Gln?Gln?Leu?Leu?Asp?Ser?Gly?Val?Cys?Lys?Val?Asp?Lys
690 695 700
cag?aac?cgt?gct?ggc?tac?agc?cct?att?atg?ctc?acc?gcc?ctg?gcc?acc 2160
Gln?Asn?Arg?Ala?Gly?Tyr?Ser?Pro?Ile?Met?Leu?Thr?Ala?Leu?Ala?Thr
705 710 715 720
ctg?aag?acc?cag?gac?gac?atc?gag?act?gtc?ctt?cag?ctc?ttc?cgg?ctt 2208
Leu?Lys?Thr?Gln?Asp?Asp?Ile?Glu?Thr?Val?Leu?Gln?Leu?Phe?Arg?Leu
725 730 735
ggc?aac?atc?aat?gcc?aaa?gcc?agc?cag?gca?gga?cag?acg?gcc?ctg?atg 2256
Gly?Asn?Ile?Asn?Ala?Lys?Ala?Ser?Gln?Ala?Gly?Gln?Thr?Ala?Leu?Met
740 745 750
ctg?gcc?gtc?agc?cac?ggg?cgg?gtg?gac?gtt?gtc?aaa?gcc?ctg?ctg?gcc 2304
Leu?Ala?Val?Ser?His?Gly?Arg?Val?Asp?Val?Val?Lys?Ala?Leu?Leu?Ala
755 760 765
tgt?gag?gca?gat?gtc?aac?gtg?caa?gat?gat?gac?ggc?tcc?acg?gcc?ctc 2352
Cys?Glu?Ala?Asp?Val?Asn?Val?Gln?Asp?Asp?Asp?Gly?Ser?Thr?Ala?Leu
770 775 780
atg?tgc?gcc?tgt?gag?cac?ggc?cac?aag?gag?atc?gcg?ggg?ctg?ctg?ctg 2400
Met?Cys?Ala?Cys?Glu?His?Gly?His?Lys?Glu?Ile?Ala?Gly?Leu?Leu?Leu
785 790 795 800
gcc?gtg?ccc?agc?tgt?gac?atc?tca?ctc?aca?gat?cgc?gat?ggg?agc?aca 2448
Ala?Val?Pro?Ser?Cys?Asp?Ile?Ser?Leu?Thr?Asp?Arg?Asp?Gly?Ser?Thr
805 810 815
gct?ctg?atg?gtg?gcc?ttg?gac?gca?ggg?cag?agt?gag?att?gcg?tcc?atg 2496
Ala?Leu?Met?Val?Ala?Leu?Asp?Ala?Gly?Gln?Ser?Glu?Ile?Ala?Ser?Met
820 825 830
ctg?tat?tcc?cgc?atg?aac?atc?aag?tgc?tcg?ttt?gcc?cca?atg?tca?gat 2544
Leu?Tyr?Ser?Arg?Met?Asn?Ile?Lys?Cys?Ser?Phe?Ala?Pro?Met?Ser?Asp
835 840 845
gac?gag?agc?cct?aca?tca?tcc?tcg?gca?gaa?gag?tag 2580
Asp?Glu?Ser?Pro?Thr?Ser?Ser?Ser?Ala?Glu?Glu
850 855
<210>2
<211>859
<212>PRT
<213〉people
<400>2
Met?Ala?Gln?Val?Leu?His?Val?Pro?Ala?Pro?Phe?Pro?Gly?Thr?Pro?Gly
1 5 10 15
Pro?Ala?Ser?Pro?Pro?Ala?Phe?Pro?Ala?Lys?Asp?Pro?Asp?Pro?Pro?Tyr
20 25 30
Ser?Val?Glu?Thr?Pro?Tyr?Gly?Tyr?Arg?Leu?Asp?Leu?Asp?Phe?Leu?Lys
35 40 45
Tyr?Val?Asp?Asp?Ile?Glu?Lys?Gly?His?Thr?Leu?Arg?Arg?Val?Ala?Val
50 55 60
Gln?Arg?Arg?Pro?Arg?Leu?Ser?Ser?Leu?Pro?Arg?Gly?Pro?Gly?Ser?Trp
65 70 75 80
Trp?Thr?Ser?Thr?Glu?Ser?Leu?Cys?Ser?Asn?Ala?Ser?Gly?Asp?Ser?Arg
85 90 95
His?Ser?Ala?Tyr?Ser?Tyr?Cys?Gly?Arg?Gly?Phe?Tyr?Pro?Gln?Tyr?Gly
100 105 110
Ala?Leu?Glu?Thr?Arg?Gly?Gly?Phe?Asn?Pro?Arg?Val?Glu?Arg?Thr?Leu
115 120 125
Leu?Asp?Ala?Arg?Arg?Arg?Leu?Glu?Asp?Gln?Ala?Ala?Thr?Pro?Thr?Gly
130 135 140
Leu?Gly?Ser?Leu?Thr?Pro?Ser?Ala?Ala?Gly?Ser?Thr?Ala?Ser?Leu?Val
145 150 155 160
Gly?Val?Gly?Leu?Pro?Pro?Pro?Thr?Pro?Arg?Ser?Ser?Gly?Leu?Ser?Thr
165 170 175
Pro?Val?Pro?Pro?Ser?Ala?Gly?His?Leu?Ala?His?Val?Arg?Glu?Gln?Met
180 185 190
Ala?Gly?Ala?Leu?Arg?Lys?Leu?Arg?Gln?Leu?Glu?Glu?Gln?Val?Lys?Leu
195 200 205
Ile?Pro?Val?Leu?Gln?Val?Lys?Leu?Ser?Val?Leu?Gln?Glu?Glu?Lys?Arg
210 215 220
Gln?Leu?Thr?Val?Gln?Leu?Lys?Ser?Gln?Lys?Phe?Leu?Gly?His?Pro?Thr
225 230 235 240
Ala?Gly?Arg?Gly?Arg?Ser?Glu?Leu?Cys?Leu?Asp?Leu?Pro?Asp?Pro?Pro
245 250 255
Glu?Asp?Pro?Val?Ala?Leu?Glu?Thr?Arg?Ser?Val?Gly?Thr?Trp?Val?Arg
260 265 270
Glu?Arg?Asp?Leu?Gly?Met?Pro?Asp?Gly?Glu?Ala?Ala?Leu?Ala?Ala?Lys
275 280 285
Val?Ala?Val?Leu?Glu?Thr?Gln?Leu?Lys?Lys?Ala?Leu?Gln?Glu?Leu?Gln
290 295 300
Ala?Ala?Gln?Ala?Arg?Gln?Ala?Asp?Pro?Gln?Pro?Gln?Ala?Trp?Pro?Pro
305 310 315 320
Pro?Asp?Ser?Pro?Val?Arg?Val?Asp?Thr?Val?Arg?Val?Val?Glu?Gly?Pro
325 330 335
Arg?Glu?Val?Glu?Val?Val?Ala?Ser?Thr?Ala?Ala?Gly?Ala?Pro?Ala?Gln
340 345 350
Arg?Ala?Gln?Ser?Leu?Glu?Pro?Tyr?Gly?Thr?Gly?Leu?Arg?Ala?Leu?Ala
355 360 365
Met?Pro?Gly?Arg?Pro?Glu?Ser?Pro?Pro?Val?Phe?Arg?Ser?Gln?Glu?Val
370 375 380
Val?Glu?Thr?Met?Cys?Pro?Val?Pro?Ala?Ala?Ala?Thr?Ser?Asn?Val?His
385 390 395 400
Met?Val?Lys?Lys?Ile?Ser?Ile?Thr?Glu?Arg?Ser?Cys?Asp?Gly?Ala?Ala
405 410 415
Gly?Leu?Pro?Glu?Val?Pro?Ala?Glu?Ser?Ser?Ser?Ser?Pro?Pro?Gly?Ser
420 425 430
Glu?Val?Ala?Ser?Leu?Thr?Gln?Pro?Glu?Lys?Ser?Thr?Gly?Arg?Val?Pro
435 440 445
Thr?Gln?Glu?Pro?Thr?His?Arg?Glu?Pro?Thr?Arg?Gln?Ala?Ala?Ser?Gln
450 455 460
Glu?Ser?Glu?Glu?Ala?Gly?Gly?Thr?Ala?Pro?Pro?Leu?Ser?Ser?Pro?Pro
465 470 475 480
Gly?Gly?Pro?Pro?Ala?Gly?Val?Arg?Ser?Ile?Met?Lys?Arg?Lys?Glu?Glu
485 490 495
Val?Ala?Asp?Pro?Thr?Ala?His?Arg?Arg?Ser?Leu?Gln?Phe?Val?Gly?Val
500 505 510
Asn?Gly?Gly?Tyr?Glu?Ser?Ser?Ser?Glu?Asp?Ser?Ser?Thr?Ala?Glu?Asn
515 520 525
Ile?Ser?Asp?Asn?Asp?Ser?Thr?Glu?Asn?Glu?Ala?Pro?Glu?Pro?Arg?Glu
530 535 540
Arg?Val?Pro?Ser?Val?Ala?Glu?Ala?Pro?Gln?Leu?Arg?Pro?Ala?Gly?Thr
545 550 555 560
Ala?Ala?Ala?Lys?Thr?Ser?Arg?Gln?Glu?Cys?Gln?Leu?Ser?Arg?Glu?Ser
565 570 575
Gln?His?Ile?Pro?Thr?Ala?Glu?Gly?Ala?Ser?Gly?Ser?Asn?Thr?Glu?Glu
580 585 590
Glu?Ile?Arg?Met?Glu?Leu?Ser?Pro?Asp?Leu?Ile?Ser?Ala?Cys?Leu?Ala
595 600 605
Leu?Glu?Lys?Tyr?Leu?Asp?Asn?Pro?Asn?Ala?Leu?Thr?Glu?Arg?Glu?Leu
610 615 620
Lys?Val?Ala?Tyr?Thr?Thr?Val?Leu?Gln?Glu?Trp?Leu?Arg?Leu?Ala?Cys
625 630 635 640
Arg?Ser?Asp?Ala?His?Pro?Glu?Leu?Val?Arg?Arg?His?Leu?Val?Thr?Phe
645 650 655
Arg?Ala?Met?Ser?Ala?Arg?Leu?Leu?Asp?Tyr?Val?Val?Asn?Ile?Ala?Asp
660 665 670
Ser?Asn?Gly?Asn?Thr?Ala?Leu?His?Tyr?Ser?Val?Ser?His?Ala?Asn?Phe
675 680 685
Pro?Val?Val?Gln?Gln?Leu?Leu?Asp?Ser?Gly?Val?Cys?Lys?Val?Asp?Lys
690 695 700
Gln?Asn?Arg?Ala?Gly?Tyr?Ser?Pro?Ile?Met?Leu?Thr?Ala?Leu?Ala?Thr
705 710 715 720
Leu?Lys?Thr?Gln?Asp?Asp?Ile?Glu?Thr?Val?Leu?Gln?Leu?Phe?Arg?Leu
725 730 735
Gly?Asn?Ile?Asn?Ala?Lys?Ala?Ser?Gln?Ala?Gly?Gln?Thr?Ala?Leu?Met
740 745 750
Leu?Ala?Val?Ser?His?Gly?Arg?Val?Asp?Val?Val?Lys?Ala?Leu?Leu?Ala
755 760 765
Cys?Glu?Ala?Asp?Val?Asn?Val?Gln?Asp?Asp?Asp?Gly?Ser?Thr?Ala?Leu
770 775 780
Met?Cys?Ala?Cys?Glu?His?Gly?His?Lys?Glu?Ile?Ala?Gly?Leu?Leu?Leu
785 790 795 800
Ala?Val?Pro?Ser?Cys?Asp?Ile?Ser?Leu?Thr?Asp?Arg?Asp?Gly?Ser?Thr
805 810 815
Ala?Leu?Met?Val?Ala?Leu?Asp?Ala?Gly?Gln?Ser?Glu?Ile?Ala?Ser?Met
820 825 830
Leu?Tyr?Ser?Arg?Met?Asn?Ile?Lys?Cys?Ser?Phe?Ala?Pro?Met?Ser?Asp
835 840 845
Asp?Glu?Ser?Pro?Thr?Ser?Ser?Ser?Ala?Glu?Glu
850 855
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005100111965A CN100354302C (en) | 2005-01-18 | 2005-01-18 | SIP gene and its coded protein and uses |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005100111965A CN100354302C (en) | 2005-01-18 | 2005-01-18 | SIP gene and its coded protein and uses |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1807450A CN1807450A (en) | 2006-07-26 |
CN100354302C true CN100354302C (en) | 2007-12-12 |
Family
ID=36839561
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2005100111965A Expired - Fee Related CN100354302C (en) | 2005-01-18 | 2005-01-18 | SIP gene and its coded protein and uses |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100354302C (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001098339A2 (en) * | 2000-06-22 | 2001-12-27 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of breast cancer |
US20020019005A1 (en) * | 1999-02-18 | 2002-02-14 | Arcaris, Inc. | Process for identification of genes encoding proteins having cell proliferation-promoting activity |
-
2005
- 2005-01-18 CN CNB2005100111965A patent/CN100354302C/en not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020019005A1 (en) * | 1999-02-18 | 2002-02-14 | Arcaris, Inc. | Process for identification of genes encoding proteins having cell proliferation-promoting activity |
WO2001098339A2 (en) * | 2000-06-22 | 2001-12-27 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of breast cancer |
Non-Patent Citations (2)
Title |
---|
SIP,a novel SRC-1 interacting protein implicated in nuclearreceptor signal pathway. Zhang,Y.等.GenBank序列号AAT57879 2004 * |
SIP,a novel SRC-1 interacting protein implicated innuclearreceptor signal pathway. Zhang,Y.等.GenBank序列号AY639929 2004 * |
Also Published As
Publication number | Publication date |
---|---|
CN1807450A (en) | 2006-07-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Heggeness et al. | Intracellular distributions of mechanochemical proteins in cultured fibroblasts | |
Rønnov-Jessen et al. | The origin of the myofibroblasts in breast cancer. Recapitulation of tumor environment in culture unravels diversity and implicates converted fibroblasts and recruited smooth muscle cells. | |
Baldi et al. | Differential expression of Rb2/p130 and p107 in normal human tissues and in primary lung cancer. | |
Chen et al. | Isolation of highly pure alveolar epithelial type I and type II cells from rat lungs | |
Berditchevski et al. | Characterization of novel complexes on the cell surface between integrins and proteins with 4 transmembrane domains (TM4 proteins). | |
US6521415B1 (en) | Tandem immuno-assay for cancer | |
Osterlund et al. | Mage-b4, a novel melanoma antigen (MAGE) gene specifically expressed during germ cell differentiation | |
Montmayeur et al. | Targeting of Gαi2 to the Golgi by alternative spliced carboxyl-terminal region | |
CN102675458A (en) | Monoclonal antibodies and methods for their use in the detection of cervical disease | |
CN107022030A (en) | Detect monoclonal antibody and kit and the application of alpha-fetoprotein | |
Fuller Jr et al. | Mullerian inhibiting substance reduction of colony growth of human gynecologic cancers in a stem cell assay | |
Nygaard et al. | Expression of annexin II in glioma cell lines and in brain tumor biopsies | |
De Luca et al. | CDC2‐related kinase PITALRE phosphorylates pRb exclusively on serine and is widely expressed in human tissues | |
Kim et al. | An unanticipated discourse of HB-EGF with VANGL2 signaling during embryo implantation | |
Deli et al. | Calcium/calmodulin‐stimulated protein kinase II is present in primary cultures of cerebral endothelial cells | |
CN100354302C (en) | SIP gene and its coded protein and uses | |
Hamada et al. | M r 85,000 membrane protein specifically expressed in adriamycin-resistant human tumor cells | |
Haas et al. | In vitro infection of lymphoid cells by thymotropic radiation leukemia virus grown in vitro. | |
Lotem et al. | Regulation of cap formation by concanavalin A and the differentiation of myeloid leukemic cells: Relationship to free and anchored surface receptors | |
CN109575130A (en) | A kind of monoclonal antibody and its preparation and application detecting HPV18 E7 albumen | |
US11175289B2 (en) | Application of TRPM8 protein, related peptide fragment and their antibodies | |
CN101058808B (en) | A p60 gene related to breast cancer, its encoded protein and its application | |
CN111944056B (en) | Apoptosis protein fusion type anti-HER-2 single chain antibody and preparation method and application thereof | |
CN101058604B (en) | FK gene and its encoded protein and application | |
Tsutsui et al. | Immunofluorescent study of non-histone protein-DNA complexes in cultured cells and lymphocytes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20071212 Termination date: 20110118 |